Microbot Medical Inc.
NASDAQ:MBOTMedical - Instruments & Supplies
-$0.06 today
- Market cap
- $65.73M
- Beta
- 1.04
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.21
Volume 0.87M
Average 1.60M
MBOT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Microbot Medical Inc.NASDAQ: MBOT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 13.7% from a year ago
Cash & equivalents stood at $3.66M at the end of Q1 FY2026, up 13.7% from a year earlier and down 6.5% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.
Context
- Cash & equivalents amounted to 4.7% of total assets at the end of Q1 FY2026, down 5.7 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +13.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 3.91M USD
- Year-over-year change
- +25.6%
- 4-year CAGR
- -26.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.91M | +25.6% |
| FY2024 | 2024-12-31 | 3.11M | +26.2% |
| FY2023 | 2023-12-31 | 2.47M | -2.0% |
| FY2022 | 2022-12-31 | 2.52M | -81.3% |
| FY2021 | 2021-12-31 | 13.49M | — |
Cash & Equivalents vs competitors
How MBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +13.7% is the 5th highest of 10, against a peer median of -39.0%.
- Cash & equivalents amounts to 4.7% of total assets for MBOT, versus a peer median of 27.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $94.06M USD | +345.0% | -33.6% | 41.7% | |
| Mar 2026 | $54.53M USD | -39.0% | +23.0% | 92.6% | |
| Mar 2026 | $35.68M USD | -54.8% | -31.3% | 17.1% | |
| Mar 2026 | CA$27.74M CAD | +19.1% | -21.2% | 88.1% | |
| Mar 2026 | $19.75M USD | +51.8% | -28.9% | 46.6% | |
| Mar 2026 | $13.2M USD | -82.3% | +4.3% | 4.9% | |
| Mar 2026 | $8.31M USD | -44.1% | -17.4% | 16.1% | |
| Mar 2026 | $5.94M USD | -39.6% | -34.3% | 27.4% | |
| Mar 2026 | $3.66M USD | +13.7% | +15.8% | 4.7% | |
| Mar 2026 | CA$1.31M CAD | +975.2% | -49.9% | 8.6% | |
| Peer median (excluding MBOT) | — | -39.0% | -28.9% | 27.4% | |
Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Microbot Medical Inc.
NASDAQ:MBOT
Intrinsic Alpha fair value
Locked
Current Price
$0.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.